Alzheimer's disease. Alzheimer disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: The intervention group, which includes 50 patients with mild to moderate Alzheimers disease between the ages of 50 and 85, will take two 250 mg capsules of hydroalc
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: Having informed consent for study participation Having a CDR score less than or equal to 2 Having an ADAS-COG score higher than or equal to 12 Ability to participate in the study
Exclusion criteria
Exclusion criteria: Inability to participate in the study Inability to continue treatment Presence of heart disease Substance abuse and alcohol addiction Taking anticoagulant drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's severity score in CDR and ADAS-COG questionnaire. Timepoint: At the beginning of the study (before the start of the intervention), at the end of every 4 weeks to three months after the start of taking the drug and placebo. Method of measurement: CDR (Clinical Dementia Rating Scale-Sum of Boxes) and ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive Subscale) questionnaires. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: End of the third month. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahdieh. Mobayyen
Kerman University of Medical Sciences
Outcome results
None listed